source
- Ono Pharma’s endocannabinoid drug ONO-1110 fails five Phase 2 trials, prompting broader concernsOno Pharma reported that its experimental endocannabinoid modulator ONO-1110 did not achieve the primary efficacy endpoint in five separate Phase 2 clinical trials. The failures span multiple indi…
- Genmab shares climb after head-and-neck cancer data as Iovance and Coherus stocks fallGenmab's shares moved higher after the company released data from a head‑and‑neck cancer trial, which investors interpreted as a positive signal for the drug's potential. In contrast, Iovance and…